1. Home
  2. STTK vs VINP Comparison

STTK vs VINP Comparison

Compare STTK & VINP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$7.30

Market Cap

683.8M

Sector

Health Care

ML Signal

HOLD

Logo Vinci Partners Investments Ltd.

VINP

Vinci Partners Investments Ltd.

HOLD

Current Price

$9.42

Market Cap

638.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
STTK
VINP
Founded
2016
2009
Country
United States
Brazil
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
683.8M
638.8M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
STTK
VINP
Price
$7.30
$9.42
Analyst Decision
Buy
Strong Buy
Analyst Count
7
2
Target Price
$10.00
$14.00
AVG Volume (30 Days)
1.3M
29.2K
Earning Date
05-01-2026
05-11-2026
Dividend Yield
N/A
5.72%
EPS Growth
53.02
N/A
EPS
N/A
N/A
Revenue
$1,000,000.00
N/A
Revenue This Year
N/A
$18.07
Revenue Next Year
N/A
$12.74
P/E Ratio
N/A
$24.41
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$9.22
52 Week High
$8.33
$13.61

Technical Indicators

Market Signals
Indicator
STTK
VINP
Relative Strength Index (RSI) 54.26 36.78
Support Level $5.87 N/A
Resistance Level $7.75 $10.28
Average True Range (ATR) 0.52 0.25
MACD -0.03 -0.03
Stochastic Oscillator 55.08 17.17

Price Performance

Historical Comparison
STTK
VINP

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About VINP Vinci Partners Investments Ltd.

Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.

Share on Social Networks: